IL17A and psoriasis: In a imiquimod psoriasis model, psoriatic inflammation increased brain IL-17A levels; administration of both peripheral anti-IL17A agents and NFκB and p38MAPK inhibitors decreased brain cytokines as well as IL17A-induced depression-like behaviours (Nadeem et al., 2017).